Who Paid My Doc
Carlos Esparza
Physical Medicine & Rehabilitation Albuquerque, NM Medical Doctor
NPI 1255399630 CMS profile 238522
3846 Masthead St Ne, Albuquerque, NM 87109
General payments
$1,256
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Carlos Esparza of Albuquerque, NM is reported in the CMS Open Payments database as having received $1,256 across 72 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 75th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $171 | 7 | |
| 2024 | General | $343 | 17 | |
| 2023 | General | $226 | 16 | |
| 2022 | General | $139 | 8 | |
| 2021 | General | $65 | 4 | |
| 2020 | General | $100 | 6 | |
| 2019 | General | $213 | 14 |
Beside peers
- Carlos Esparza
- Physical Medicine & Rehabilitation median
- Middle half of Physical Medicine & Rehabilitation
- National median
In program year 2025, general payments to Carlos Esparza were reported at $171. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.
Show as a table
| Year | Carlos Esparza | Physical Medicine & Rehabilitation median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $213 | $133 | $45–$390 | $163 |
| 2020 | $100 | $88 | $29–$272 | $114 |
| 2021 | $65 | $116 | $33–$360 | $132 |
| 2022 | $139 | $123 | $40–$378 | $149 |
| 2023 | $226 | $131 | $43–$396 | $160 |
| 2024 | $343 | $141 | $45–$409 | $164 |
| 2025 | $171 | $139 | $48–$410 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
621
Drug cost
$16,773
Branded share of claims
35.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hysingla Er Hydrocodone Bitartrate | Brand | 11 | $3,731 | |
| Oxycodone Hcl | Generic | 135 | $3,617 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 121 | $3,045 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 68 | $2,776 | |
| Gabapentin | Generic | 89 | $1,415 | |
| Tizanidine Hcl | Generic | 51 | $768 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 20 | $327 | |
| Cyclobenzaprine Hcl | Generic | 16 | $240 | |
| Pregabalin | Generic | 17 | $194 | |
| Celecoxib | Generic | 18 | $170 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 44 billing codesPaid by Medicare
$87,194
Medicare patients
153
Services billed
2,831
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 65% | |
| Diabetes | 32% | |
| Depression | 25% | |
| Osteoporosis | 22% | |
| Ischemic heart disease | 19% | |
| Chronic kidney disease | 18% | |
| COPD | 12% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone sodium succinate, up to 40 mg J2920 | Office | 20 | 192 | $629 |
| Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml Q9965 | Office | 70 | 524 | $575 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 61 | 703 | $530 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 23 | 271 | $60 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
72 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Physical Medicine & Rehabilitation in New Mexico
Practitioners in the same specialty and state, ranked by reported value.
All Physical Medicine & Rehabilitation
Everyone recorded under this specialty, nationwide.
Doctors in New Mexico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.